China SXT Pharmaceuticals (SXTC) Other Non-Current Assets (2019 - 2024)
China SXT Pharmaceuticals (SXTC) posted quarterly Other Non-Current Assets of $8.5 million for Q3 2024, up 2.89% quarter-over-quarter from $8.3 million in Q1 2024.
China SXT Pharmaceuticals (SXTC) Other Non-Current Assets (2019 - 2024) Analysis & Trends
China SXT Pharmaceuticals' Other Non-Current Assets history runs 6 years deep, the most recent figure standing at $8.5 million for Q3 2024.
- In Q3 2024, Other Non-Current Assets changed N/A year-over-year to $8.5 million; the TTM figure through Sep 2024 stood at $8.5 million (changed N/A YoY), while the FY2024 annual figure was $8.3 million, down 4.88% from the prior year.
- Other Non-Current Assets for Q3 2024 stood at $8.5 million, up from $8.3 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $9.5 million in Q1 2022, with the low at $2.9 million in Q3 2020.
- The 5-year median for Other Non-Current Assets is $8.6 million (2023), against an average of $8.1 million.
- The sharpest annual moves came in 2021 and 2022: Other Non-Current Assets jumped 225.9% in 2021, then declined 9.42% in 2022.
- China SXT Pharmaceuticals' Other Non-Current Assets stood at $2.9 million in 2020, then surged by 225.9% to $9.3 million in 2021, then fell by 9.42% to $8.4 million in 2022, then gained by 3.58% to $8.7 million in 2023, then fell by 2.14% to $8.5 million in 2024.
- Business Quant data shows SXTC's Other Non-Current Assets at $8.5 million in Q3 2024, $8.3 million in Q1 2024, and $8.7 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 13.00 Mn |
| 10 | China SXT Pharmaceuticals | 34,451.28 | -28.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 8.55 Mn |
| Mar 31, 2024 | 8.31 Mn |
| Mar 31, 2023 | 8.74 Mn |
| Sep 30, 2022 | 8.43 Mn |
| Mar 31, 2022 | 9.46 Mn |
| Sep 30, 2021 | 9.31 Mn |
| Mar 31, 2021 | 9.16 Mn |
| Sep 30, 2020 | 2.86 Mn |
| Sep 30, 2019 | -3.61 Mn |